Pharma Focus Asia
KP - Choose our fully recyclable blister films

New Simoa® phospho-Tau 181 (pTau-181) Blood Test Discovered for Alzheimer’s Disease

Quanterix Corporation discovers new Blood-Based pTau-181 Assay for Alzheimer’s Disease.  The Simoa® phospho-Tau 181 (pTau-181) blood test will be used for diagnostic evaluation of Alzheimer’s Disease (AD).

With the use of HD-X immunoassay system, the pTau-181 concentration in human serum and plasma with the help of blood-based assay. The test is applicable for adult patients with the age of 50 years and above 50 years with cognitive impairment assessed for AD. Moreover, for other causes of cognitive decline it is used as an diagnostic evaluation for AD. In order to obtain final clinical diagnosis, the assay will be interpreted along with other diagnostic tools.

This technology has the ability to detect low-abundance markers in a blood sample which unlocks the possibility of earlier, more accessible, non-invasive diagnosis of disease, including AD.

U.S. Food and Drug Administration (FDA) grants breakthrough device designation for Blood-Based pTau-181 Assay for Alzheimer’s Disease.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoBora Pharmaceuticals - Free WhitepaperThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023
MasterControl - 6 Essential Features in an eQMS